178 related articles for article (PubMed ID: 19050079)
1. A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities.
Garman KS; Acharya CR; Edelman E; Grade M; Gaedcke J; Sud S; Barry W; Diehl AM; Provenzale D; Ginsburg GS; Ghadimi BM; Ried T; Nevins JR; Mukherjee S; Hsu D; Potti A
Proc Natl Acad Sci U S A; 2008 Dec; 105(49):19432-7. PubMed ID: 19050079
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive value of an autophagy-related signature for early relapse in stages I-III colon cancer.
Mo S; Dai W; Xiang W; Li Y; Feng Y; Zhang L; Li Q; Cai G
Carcinogenesis; 2019 Jul; 40(7):861-870. PubMed ID: 30933267
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.
Wang Y; Jatkoe T; Zhang Y; Mutch MG; Talantov D; Jiang J; McLeod HL; Atkins D
J Clin Oncol; 2004 May; 22(9):1564-71. PubMed ID: 15051756
[TBL] [Abstract][Full Text] [Related]
5. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.
Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968
[TBL] [Abstract][Full Text] [Related]
6. A 12-gene genomic instability signature predicts clinical outcomes in multiple cancer types.
Mettu RK; Wan YW; Habermann JK; Ried T; Guo NL
Int J Biol Markers; 2010; 25(4):219-28. PubMed ID: 21161944
[TBL] [Abstract][Full Text] [Related]
7. Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction.
Wan YW; Sabbagh E; Raese R; Qian Y; Luo D; Denvir J; Vallyathan V; Castranova V; Guo NL
PLoS One; 2010 Aug; 5(8):e12222. PubMed ID: 20808922
[TBL] [Abstract][Full Text] [Related]
8. Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer.
Tian X; Zhu X; Yan T; Yu C; Shen C; Hu Y; Hong J; Chen H; Fang JY
Mol Oncol; 2017 Nov; 11(11):1544-1560. PubMed ID: 28796930
[TBL] [Abstract][Full Text] [Related]
9. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer.
Smith JJ; Deane NG; Wu F; Merchant NB; Zhang B; Jiang A; Lu P; Johnson JC; Schmidt C; Bailey CE; Eschrich S; Kis C; Levy S; Washington MK; Heslin MJ; Coffey RJ; Yeatman TJ; Shyr Y; Beauchamp RD
Gastroenterology; 2010 Mar; 138(3):958-68. PubMed ID: 19914252
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-driven gene expression is an independent prognostic factor in stage II and III colon cancer patients.
Dekervel J; Hompes D; van Malenstein H; Popovic D; Sagaert X; De Moor B; Van Cutsem E; D'Hoore A; Verslype C; van Pelt J
Clin Cancer Res; 2014 Apr; 20(8):2159-68. PubMed ID: 24486594
[TBL] [Abstract][Full Text] [Related]
11. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.
Gray RG; Quirke P; Handley K; Lopatin M; Magill L; Baehner FL; Beaumont C; Clark-Langone KM; Yoshizawa CN; Lee M; Watson D; Shak S; Kerr DJ
J Clin Oncol; 2011 Dec; 29(35):4611-9. PubMed ID: 22067390
[TBL] [Abstract][Full Text] [Related]
12. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.
Acharya CR; Hsu DS; Anders CK; Anguiano A; Salter KH; Walters KS; Redman RC; Tuchman SA; Moylan CA; Mukherjee S; Barry WT; Dressman HK; Ginsburg GS; Marcom KP; Garman KS; Lyman GH; Nevins JR; Potti A
JAMA; 2008 Apr; 299(13):1574-87. PubMed ID: 18387932
[TBL] [Abstract][Full Text] [Related]
13. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
14. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
15. Individualized predictive signatures for 5-fluorouracil-based chemotherapy in right- and left-sided colon cancer.
Song K; Zhao W; Wang W; Zhang N; Wang K; Chang Z
Cancer Sci; 2018 Jun; 109(6):1939-1948. PubMed ID: 29700901
[TBL] [Abstract][Full Text] [Related]
16. Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer.
Sperlich A; Balmert A; Doll D; Bauer S; Franke F; Keller G; Wilhelm D; Mur A; Respondek M; Friess H; Nitsche U; Janssen KP
BMC Cancer; 2018 Oct; 18(1):998. PubMed ID: 30340556
[TBL] [Abstract][Full Text] [Related]
17. Association of the Collagen Signature in the Tumor Microenvironment With Recurrence and Survival of Patients With T4N0M0 Colon Cancer.
Chen W; Dong S; Liu X; Wang G; Xu S; Lei S; Zhuo S; Yan J
Dis Colon Rectum; 2021 May; 64(5):563-575. PubMed ID: 33538520
[TBL] [Abstract][Full Text] [Related]
18. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
19. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
[TBL] [Abstract][Full Text] [Related]
20. Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer.
Jiang Y; Casey G; Lavery IC; Zhang Y; Talantov D; Martin-McGreevy M; Skacel M; Manilich E; Mazumder A; Atkins D; Delaney CP; Wang Y
J Mol Diagn; 2008 Jul; 10(4):346-54. PubMed ID: 18556775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
